BAXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
BAXTER INTERNATIONAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$24.99−0.29 (-1.15%)
Close on Oct 19, 2026
- Market cap
- $12.94B
- P/E (TTM)
- –
- Dividend yield
- 2.08%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
557M of 517M shares
Institutional holders
685
106 new, 74 sold out
Net institutional buying
28M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Pzena Investment Management LLC | 65,347,621 | 12.70% | 13G (passive) amendment | Mar 31, 2026 |
| Dodge & Cox | 57,396,370 | 11.20% | 13G (passive) amendment | Sep 30, 2025 |
| Abigail P. Johnson | 52,972,914 | 10.30% | 13G (passive) amendment | May 29, 2026 |
| BlackRock Portfolio Management LLC | 44,925,341 | 8.70% | 13G (passive) amendment | Dec 31, 2025 |
| Vanguard Capital Management | 38,033,907 | 7.36% | 13G (passive) | Mar 31, 2026 |
| FMR LLC | 34,811,770 | 6.80% | 13G (passive) | Dec 31, 2025 |
| BlackRock, Inc. | 33,109,852 | 6.40% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BAX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 81,842,105 | 15.83% | $1.74B | +2,441,441 | 0.03% |
| Pzena Investment Management LLC | 65,295,393 | 12.63% | $1.39B | +767,570 | 4.09% |
| Dodge & Cox | 58,386,345 | 11.29% | $1.24B | +1,131,775 | 0.65% |
| FMR LLC | 53,913,831 | 10.43% | $1.15B | +7,649,027 | 0.05% |
| Vanguard Capital Management LLC | 33,754,280 | 6.53% | $719.64M | +247,305 | 0.02% |
| Vanguard Portfolio Management LLC | 24,057,190 | 4.65% | $512.90M | +63,835 | 0.02% |
| State Street Corp | 20,600,468 | 3.98% | $439.40M | +620,511 | 0.01% |
| Greenhaven Associates Inc | 14,285,228 | 2.76% | $304.56M | −22,460 | 3.52% |
| Geode Capital Management, LLC | 14,123,689 | 2.73% | $300.59M | +360,724 | 0.02% |
| Invesco Ltd. | 12,361,881 | 2.39% | $263.56M | −759,290 | 0.02% |
| UBS Group AG | 9,529,309 | 1.84% | $203.16M | +5,209,812 | 0.03% |
| First Pacific Advisors, LP | 7,618,145 | 1.47% | $162.42M | +917,220 | 2.01% |
| Goldman Sachs Group Inc | 7,150,462 | 1.38% | $152.45M | +3,280,907 | 0.01% |
| Equity Investment Corp | 6,886,265 | 1.33% | $146.82M | +516,271 | 2.80% |
| Morgan Stanley | 6,359,790 | 1.23% | $135.59M | −988,182 | 0.01% |
| Bank Of America Corp /De/ | 6,237,950 | 1.21% | $132.99M | +71,817 | 0.01% |
| State Farm Mutual Automobile Insurance Co | 6,225,060 | 1.20% | $132.72M | – | 0.09% |
| Charles Schwab Investment Management Inc | 5,996,711 | 1.16% | $127.85M | +407,157 | 0.02% |
| Dimensional Fund Advisors LP | 5,612,144 | 1.09% | $119.68M | −319,647 | 0.02% |
| Northern Trust Corp | 4,864,004 | 0.94% | $103.70M | +516,686 | 0.01% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 685 | 557M | 100.0% | 106 / 250 | 194 / 74 | 48M | 21M |
| Q1 2026 | 662 | 529M | 100.0% | 82 / 190 | 261 / 120 | 114M | 74M |
| Q4 2025 | 710 | 552M | 100.0% | 112 / 240 | 237 / 120 | 91M | 48M |
| Q3 2025 | 732 | 510M | 98.6% | 87 / 252 | 269 / 116 | 81M | 69M |
| Q2 2025 | 774 | 500M | 96.8% | 71 / 266 | 298 / 127 | 31M | 22M |
| Q1 2025 | 841 | 491M | 95.1% | 124 / 277 | 305 / 96 | 36M | 26M |
| Q4 2024 | 824 | 483M | 93.4% | 114 / 250 | 333 / 170 | 46M | 36M |
| Q3 2024 | 899 | 475M | 91.8% | 121 / 305 | 320 / 93 | 109M | 33M |
| Q2 2024 | 879 | 462M | 89.3% | 98 / 278 | 324 / 140 | 45M | 61M |
| Q1 2024 | 935 | 479M | 92.6% | 115 / 313 | 322 / 79 | 29M | 25M |
| Q4 2023 | 913 | 475M | 92.0% | 127 / 262 | 376 / 111 | 75M | 48M |
| Q3 2023 | 909 | 448M | 86.7% | 77 / 285 | 378 / 133 | 61M | 53M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of BAX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Dodge & Cox Stock Fund | 38,623,700 | 7.47% | $823.46M | 0.70% | Jun 30, 2026 |
| BlackRock Equity Dividend Fund | 18,965,221 | 3.67% | $496.13M | 2.43% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 16,397,162 | 3.17% | $349.59M | 0.02% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 13,382,913 | 2.59% | $285.32M | 0.02% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 11,833,128 | 2.29% | $252.28M | 0.13% | Jun 30, 2026 |
| Vanguard Windsor Fund | 10,439,598 | 2.02% | $273.10M | 1.08% | Jul 31, 2026 |
| Invesco S&P 500 Equal Weight ETF | 9,173,988 | 1.77% | $239.99M | 0.25% | Jul 31, 2026 |
| Fidelity Series Large Cap Stock Fund | 8,971,214 | 1.74% | $191.27M | 0.66% | Jun 30, 2026 |
| Vanguard Small-Cap Value Index Fund | 7,499,986 | 1.45% | $159.90M | 0.24% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 7,153,018 | 1.38% | $134.33M | 0.05% | May 31, 2026 |
| iShares Core S&P 500 ETF | 7,103,359 | 1.37% | $151.44M | 0.02% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 6,583,965 | 1.27% | $123.65M | 0.01% | May 31, 2026 |
| Fidelity Growth and Income Portfolio | 4,824,800 | 0.93% | $126.22M | 0.85% | Jul 31, 2026 |
| FPA Crescent Fund | 4,541,166 | 0.88% | $96.82M | 0.78% | Jun 30, 2026 |
| Vanguard Selected Value Fund | 3,672,438 | 0.71% | $96.07M | 1.38% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Andrew P. Hider | President and CEO, Director | 518,447 | 0.10% | Sep 3, 2026 |
| Bernard Heine | AVP, Finance InterimCAO&Cntrlr | 32,840 | 0.01% | Sep 18, 2026 |
| Julie Foster | President, Front Line Care | 29,164 | 0.01% | Sep 3, 2026 |
| James Teaff | President, CCS | 30,370 | 0.01% | Sep 3, 2026 |
| Steven P. Wallace | President, Adv. Surgery | 70,128 | 0.01% | Jun 3, 2026 |
| Anita A. Zielinski | SVP, Interim CFO, CAO & Cntrlr | 59,714 | 0.01% | Jun 3, 2026 |
| Maria Cecilia Soriano | Group Pres., ITT & Pharma. | 75,045 | 0.01% | Mar 10, 2026 |
| Joel T. Grade | EVP and CFO | 271,674 | 0.05% | Mar 10, 2026 |
| David S. Rosenbloom | EVP and General Counsel | 138,216 | 0.03% | Mar 10, 2026 |
| Reazur Rasul | EVP,Group Pres,Healthcare | 125,557 | 0.02% | Mar 10, 2026 |
| Cynthia Carlisle | Executive Vice President, CHRO | 0 | – | Mar 3, 2026 |
| Jeanne K. Mason | EVP, Chief HR Officer | 199,853 | 0.04% | Dec 16, 2025 |
| Alok Sonig | EVP,Group President,Pharma | 128,219 | 0.02% | Sep 4, 2025 |
| James W. Borzi | EVP,Chief Supply Chain Officer | 71,948 | 0.01% | Sep 4, 2025 |
| Heather Knight | EVP, Chief Operating Officer | 177,362 | 0.03% | Mar 10, 2025 |
| Christopher A. Toth | EVP, Group Pres, Kidney Care | 105,186 | 0.02% | Feb 4, 2025 |
| Jose E. Almeida | Chairman, CEO, President | 568,565 | 0.11% | Dec 17, 2024 |
| Michael R. McDonnell | Director | 14,647 | 0.00% | May 7, 2026 |
| Patricia Morrison | Director | 42,386 | 0.01% | May 7, 2026 |
| Nancy M. Schlichting | Director | 34,994 | 0.01% | May 7, 2026 |
| Jeffrey A. Craig | Director | 23,662 | 0.00% | May 7, 2026 |
| David S. Wilkes | Director | 37,076 | 0.01% | May 7, 2026 |
| David Brent Shafer | Director | 72,804 | 0.01% | May 7, 2026 |
| William A. Ampofo II | Director | 30,375 | 0.01% | May 7, 2026 |
| Amy McBride Wendell | Director | 44,235 | 0.01% | May 7, 2026 |
| Stephen H. Rusckowski | Director | 16,499 | 0.00% | May 8, 2025 |
| Stephen N. Oesterle | Director | 35,847 | 0.01% | May 8, 2025 |
| Cathy R. Smith | Director | 30,345 | 0.01% | May 8, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Julie Foster President, Front Line Care | Sep 2, 2026 | Tax withholding | −2,098 | $25.70 | $53.92K | 29,164 |
| Andrew P. Hider President and CEO, Director | Sep 2, 2026 | Tax withholding | −54,276 | $25.70 | $1.39M | 518,447 |
| James Teaff President, CCS | Sep 1, 2026 | Tax withholding | −750 | $25.48 | $19.11K | 30,370 |
| Steven P. Wallace President, Adv. Surgery | Jun 2, 2026 | Tax withholding | −153 | $18.68 | $2.86K | 70,128 |
| James Teaff President, CCS | Jun 2, 2026 | Tax withholding | −321 | $18.68 | $6.00K | 31,063 |
| Anita A. Zielinski SVP, Interim CFO, CAO & Cntrlr | Jun 1, 2026 | Award | +13,426 | – | – | 59,714 |
| Patricia Morrison Director | May 5, 2026 | Award | +12,836 | – | – | 42,386 |
| Nancy M. Schlichting Director | May 5, 2026 | Award | +12,836 | – | – | 34,994 |
| Jeffrey A. Craig Director | May 5, 2026 | Award | +12,836 | – | – | 23,662 |
| David S. Wilkes Director | May 5, 2026 | Award | +12,836 | – | – | 37,076 |
| David Brent Shafer Director | May 5, 2026 | Award | +12,836 | – | – | 72,804 |
| William A. Ampofo II Director | May 5, 2026 | Award | +12,836 | – | – | 30,375 |
| Amy McBride Wendell Director | May 5, 2026 | Award | +12,836 | – | – | 44,235 |
| Michael R. McDonnell Director | May 5, 2026 | Award | +12,836 | – | – | 14,647 |
| Joel T. Grade EVP and CFO | Mar 6, 2026 | Tax withholding | −8,153 | $17.69 | $144.23K | 271,674 |
| Reazur Rasul EVP,Group Pres,Healthcare | Mar 6, 2026 | Tax withholding | −12,674 | $17.69 | $224.20K | 125,557 |
| Anita A. Zielinski SVP, CAO and Controller | Mar 6, 2026 | Tax withholding | −1,932 | $17.69 | $34.18K | 46,281 |
| Maria Cecilia Soriano Group Pres., ITT & Pharma. | Mar 6, 2026 | Tax withholding | −2,848 | $17.69 | $50.38K | 75,045 |
| David S. Rosenbloom EVP and General Counsel | Mar 6, 2026 | Tax withholding | −6,620 | $17.69 | $117.11K | 138,216 |
| David S. Rosenbloom EVP and General Counsel | Mar 2, 2026 | Tax withholding | −1,336 | $19.69 | $26.31K | 144,837 |
| Maria Cecilia Soriano Group Pres., ITT & Pharma. | Mar 2, 2026 | Tax withholding | −1,852 | $19.69 | $36.47K | 77,894 |
| Reazur Rasul EVP,Group Pres,Healthcare | Mar 2, 2026 | Tax withholding | −1,614 | $19.69 | $31.78K | 138,231 |
| Andrew P. Hider President and CEO, Director | Feb 27, 2026 | Award | +201,804 | – | – | 572,239 |
| Anita A. Zielinski SVP, CAO and Controller | Feb 27, 2026 | Award | +30,864 | – | – | 48,214 |
| David S. Rosenbloom EVP and General Counsel | Feb 27, 2026 | Award | +26,709 | – | – | 146,173 |
| Joel T. Grade EVP and CFO | Feb 27, 2026 | Award | +42,735 | – | – | 279,828 |
| Maria Cecilia Soriano Group Pres., ITT & Pharma. | Feb 27, 2026 | Award | +23,742 | – | – | 79,748 |
| Cynthia Carlisle Executive Vice President, CHRO | Feb 27, 2026 | Award | +11,871 | – | – | 29,677 |
| Cynthia Carlisle Executive Vice President, CHRO | Feb 27, 2026 | Award | +17,806 | – | – | 17,806 |
| Michael R. McDonnell Director | Feb 13, 2026 | Award | +1,811 | – | – | 1,811 |
| Joel T. Grade EVP and CFO | Feb 9, 2026 | Award | +30,504 | – | – | 246,048 |
| Joel T. Grade EVP and CFO | Feb 9, 2026 | Tax withholding | −9,144 | $21.73 | $198.70K | 236,904 |
| Maria Cecilia Soriano Group Pres., ITT & Pharma. | Feb 9, 2026 | Tax withholding | −918 | $21.73 | $19.95K | 56,006 |
| Maria Cecilia Soriano Group Pres., ITT & Pharma. | Feb 9, 2026 | Award | +2,273 | – | – | 56,924 |
| David S. Rosenbloom EVP and General Counsel | Feb 9, 2026 | Award | +17,055 | – | – | 124,689 |
| David S. Rosenbloom EVP and General Counsel | Feb 9, 2026 | Tax withholding | −5,225 | $21.73 | $113.54K | 119,464 |
| Reazur Rasul EVP,Group Pres,Healthcare | Feb 9, 2026 | Tax withholding | −5,770 | $21.73 | $125.38K | 139,846 |
| Reazur Rasul EVP,Group Pres,Healthcare | Feb 9, 2026 | Award | +18,951 | – | – | 145,616 |
| Jeanne K. Mason EVP, Chief HR Officer | Dec 12, 2025 | Tax withholding | −650 | $19.15 | $12.45K | 199,853 |
| Joel T. Grade EVP and CFO | Dec 1, 2025 | Tax withholding | −8,288 | $19.08 | $158.14K | 215,151 |
| Alok Sonig EVP,Group President,Pharma | Sep 2, 2025 | Tax withholding | −3,191 | $24.17 | $77.13K | 128,219 |
| James W. Borzi EVP,Chief Supply Chain Officer | Sep 2, 2025 | Tax withholding | −1,848 | $24.17 | $44.67K | 71,948 |
| Joel T. Grade EVP and CFO | Sep 2, 2025 | Award | +102,712 | – | – | 222,560 |
| Andrew P. Hider President and CEO, Director | Sep 2, 2025 | Award | +131,813 | – | – | 368,050 |
| Andrew P. Hider President and CEO, Director | Sep 2, 2025 | Award | +236,237 | – | – | 236,237 |
| David Brent Shafer Director | Aug 19, 2025 | Tax withholding | −31,337 | $24.33 | $762.43K | 59,446 |
| David S. Rosenbloom EVP and General Counsel | Jun 2, 2025 | Tax withholding | −16,548 | $29.55 | $488.99K | 106,327 |
| William A. Ampofo II Director | May 6, 2025 | Award | +7,183 | – | – | 17,299 |
| Cathy R. Smith Director | May 6, 2025 | Award | +7,183 | – | – | 30,345 |
| Amy McBride Wendell Director | May 6, 2025 | Award | +7,183 | – | – | 31,222 |
| David S. Wilkes Director | May 6, 2025 | Award | +7,183 | – | – | 23,906 |
| Stephen N. Oesterle Director | May 6, 2025 | Award | +7,183 | – | – | 35,847 |
| Stephen H. Rusckowski Director | May 6, 2025 | Award | +7,183 | – | – | 16,499 |
| Patricia Morrison Director | May 6, 2025 | Award | +7,183 | – | – | 29,137 |
| Nancy M. Schlichting Director | May 6, 2025 | Award | +7,183 | – | – | 21,850 |
| Jeffrey A. Craig Director | May 6, 2025 | Award | +7,183 | – | – | 10,672 |
| David S. Rosenbloom EVP and General Counsel | Mar 6, 2025 | Tax withholding | −4,922 | $35.44 | $174.44K | 104,780 |
| David S. Rosenbloom EVP and General Counsel | Mar 6, 2025 | Award | +17,658 | – | – | 122,438 |
| Alok Sonig EVP,Group President,Pharma | Mar 6, 2025 | Award | +29,966 | – | – | 130,298 |
| Alok Sonig EVP,Group President,Pharma | Mar 6, 2025 | Tax withholding | −10,839 | $35.44 | $384.13K | 100,332 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| N. Oesterle Rev Trust Stephen Former Affiliate | May 18, 2026 | 36,347 | $645.24K | May 18, 2026 | Open Market Purchase |
| Brian Stevens Officer | Sep 16, 2024 | 976 | $39.05K | Sep 16, 2024 | OTHER SP SHARES |
| Brian Stevens Officer | Sep 13, 2024 | 16,063 | $639.46K | Sep 13, 2024 | PERFORMANCE SHARES |
| Mason Jeanne Officer | Mar 1, 2024 | 64,488 | $2.62M | Mar 1, 2024 | Stock Option Exercise |